Robin Carhart-Harris is one of the world's leading researchers in psychedelic neuroscience. As the founding Director of the Centre for Psychedelic Research at Imperial College London, he pioneered the first modern brain imaging studies of psilocybin in humans using fMRI. His landmark work introduced the Entropic Brain Hypothesis (2014) — proposing that consciousness exists on a spectrum of neural entropy — and the REBUS model (Relaxed Beliefs Under Psychedelics, 2019), which offers a unified theory of how psychedelics produce therapeutic change by loosening the brain's top-down predictive framework. His research has directly established the neurobiological basis for psilocybin's antidepressant effects.
Before joining Imperial, Carhart-Harris completed his PhD at the University of Bristol, where he began investigating the neurobiological basis of Freudian concepts using modern imaging tools — an unusual intellectual bridge that would characterize his career. His early work proposed that psychedelics could provide an experimental model for primary consciousness: the more primordial, less structured mode of cognition that Freud called the "primary process" and that developmental psychology associates with early childhood and dream states.
The clinical implications of his theoretical work became apparent in the first psilocybin-for-depression pilot study he led at Imperial (2016), published in Lancet Psychiatry. All 12 treatment-resistant patients showed significant improvement; 5 met criteria for remission at 3 months. For patients who had failed multiple antidepressants and years of therapy, these were not incremental improvements — they were transformations. The study helped shift psilocybin from fringe curiosity to serious Phase 2 and Phase 3 clinical investigation.
Carhart-Harris relocated to UCSF in 2021 to lead the Neuroscape Psychedelics Division, bringing the world's most prominent psychedelic neuroscience program to North America. He continues to produce foundational research on the neural correlates of psychedelic experience, the neuroscience of therapeutic mechanisms, and the psychopharmacology of altered states of consciousness. His publication record exceeds 100 peer-reviewed papers, with total citations approaching 20,000.